Clinical Trials on Advanced Milignant Gliomas in United Kingdom

Total 6175 results

Mirati Therapeutics Inc.
Aadi Bioscience, Inc.

Active, not recruiting

Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)

NSCLC | Metastatic Cancer | Advanced Cancer | Solid Tumor, Adult | Malignant Neoplastic Disease

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute; Columbia University; Schering-Plough

Completed

Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma

Glioblastoma | Gliomas

United States
Nottingham University Hospitals NHS Trust

Active, not recruiting

REpurposing SirolimUS in Compensated Advanced Chronic Liver Disease. The RESUS Proof of Concept Study (RESUS)

Advanced Chronic Liver Disease

United Kingdom
Dana-Farber Cancer Institute
National Cancer Institute (NCI); Eisai Inc.

Completed

Effect of Perampanel on Peritumoral Hyperexcitability in HGG

Seizures | Surgery | Glioma, Malignant

United States
National Cancer Institute (NCI)

Recruiting

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Glioblastoma | Malignant Glioma | Gliosarcoma

United States
Duke University
Genentech, Inc.; Millennium Pharmaceuticals, Inc.

Completed

Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma

Glioblastoma | Gliosarcoma

United States
Duke University
Genentech, Inc.; OSI Pharmaceuticals

Completed

Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme

Glioblastoma | Gliosarcoma

United States
Sequana Medical N.V.

Completed

Retrospective Study in the Use of the Alfapump and the Treatment of Malignant Ascites

Malignant Ascites

Germany, Switzerland, United Kingdom
RasCal Therapeutics, Inc.

Recruiting

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Glioblastoma | Pancreatic Cancer | Lung Cancer | Colon Cancer | Advanced Malignant Solid Neoplasm | RAS Mutation

United States
Celldex Therapeutics

Completed

Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme (ACT III)

Malignant Glioma

United States
Constantinos Hadjipanayis
National Cancer Institute (NCI); NX PharmaGen

Withdrawn

More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery

Glioblastoma | Brain Cancer | Brain Tumors | Brain Tumor, Recurrent | Benign Neoplasms, Brain | Brain Neoplasms, Benign | Brain Neoplasms, Malignant | Brain Tumor, Primary | Intracranial Neoplasms | Neoplasms, Brain | Neoplasms, Intracranial | Primary Brain Neoplasms | Primary Malignant Brain Neoplasms | Primary Malignant... and other conditions

United States
Jeffrey N. Bruce
National Cancer Institute (NCI)

Completed

Chronic Convection Enhanced Delivery of Topotecan

Gliomas

United States
Lawrence D Recht
Sanofi

Recruiting

Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma

Glioblastoma | Malignant Glioma | Gliosarcoma | Glioblastoma With Primitive Neuronal Component | Oligodendroglial Component Present

United States
Istari Oncology, Inc.
National Cancer Institute (NCI); Duke University; Brain Tumor Research Charity...

Completed

PVSRIPO for Recurrent Glioblastoma (GBM) (PVSRIPO)

Glioma | Glioblastoma | Malignant Glioma | GBM

United States
Duke University
Genentech, Inc.; Schering-Plough

Completed

Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma

Glioblastoma Multiforme

United States
RS Oncology LLC

Recruiting

Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Mesothelioma | Malignant Pleural Mesothelioma | Pleural Effusion, Malignant | Mesotheliomas Pleural | Malignant Pleural Effusion | Mesothelioma; Lung

United Kingdom
Duke University
Genentech, Inc.

Completed

Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

Glioblastoma | Gliosarcoma

United States
Vall d'Hebron Institute of Oncology
Taisho Pharmaceutical Co., Ltd.; Roche Pharma AG; Iqvia Pty Ltd; Janssen, LP

Recruiting

A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (BoB)

Advanced Solid Tumor

Spain, France, Germany, Netherlands, Sweden, United Kingdom, Italy
National Cancer Institute (NCI)

Active, not recruiting

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Ikena Oncology

Recruiting

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Colorectal Cancer | Pancreatic Cancer | Thyroid Carcinoma | Solid Tumor, Adult | Malignant Melanoma | Non-Small Cell Lung Carcinoma | BRAF Gene Mutation | Gliomas, Malignant | Ras (Kras or Nras) Gene Mutation | CRAF Gene Mutation

United States
UCB Biopharma SRL

Completed

A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, United Kingdom
Nuvectis Pharma, Inc.

Recruiting

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

Advanced Solid Tumor

United States, United Kingdom
Beth Israel Medical Center
St. Luke's-Roosevelt Hospital Center

Terminated

Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma (STRONG)

Glioblastoma | Malignant Glioma | Anaplastic Astrocytoma | Brain Tumors

United States
University of California, San Francisco
BeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology Consortium

Recruiting

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PNOC017)

Glioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II Glioma

United States
National Cancer Institute (NCI)

Completed

Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma

United States
Katy Peters
Merck Sharp & Dohme LLC; Genentech, Inc.

Completed

Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas

Glioblastoma | Brain Tumor

United States
Istari Oncology, Inc.
Duke University

Active, not recruiting

PVSRIPO in Recurrent Malignant Glioma

Malignant Glioma

United States
Fabio Iwamoto, MD
Bristol-Myers Squibb

Active, not recruiting

Nivolumab for Recurrent or Progressive IDH Mutant Gliomas

Gliomas

United States
Cancer Research UK
Teon Therapeutics, Inc.

Recruiting

TT-702 in Patients With Advanced Solid Tumours. (CURATE)

Advanced Solid Tumors

United Kingdom
University of Miami

Recruiting

Non-invasive Glioma Characterization Through Molecular Imaging

Glioma | Brain Tumor | Malignant Glioma | Primary Brain Tumor | Malignant Primary Brain Tumor

United States
BioInvent International AB
Merck Sharp & Dohme LLC

Recruiting

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Advanced Malignancies

United Kingdom, Denmark, Hungary, Russian Federation
European Organisation for Research and Treatment...

Completed

Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma

Malignant Mesothelioma

United Kingdom
National Cancer Institute (NCI)
GlaxoSmithKline; Novartis Pharmaceuticals

Active, not recruiting

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Hematopoietic and Lymphoid Cell Neoplasm | Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable...

United States
Verastem, Inc.

Terminated

A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma

Relapsed Malignant Mesothelioma

United States, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
University of Warwick
University Hospitals Coventry and Warwickshire NHS Trust

Completed

Evaluating the Integration of the Recommended Summary Plan for Emergency Care Treatment (ReSPECT) Into Primary Care

Advance Care Planning

United Kingdom
University College, London
University of Sheffield; Asthma + Lung UK; Mesothelioma UK

Recruiting

Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma (HIT-Meso)

Malignant Pleural Mesothelioma

United Kingdom
Wales Cancer Trials Unit
Velindre NHS Trust; June Hancock Mesothelioma Research Fund; Velindre Cancer...

Unknown

A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma (SKOPOS)

Mesothelioma | Malignant | Pleural

United Kingdom
Nader Sanai
GlaxoSmithKline; University of California, San Francisco; Barrow Neurological... and other collaborators

Recruiting

Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

Glioma | Glioblastoma | Glioblastoma Multiforme | GBM | Glioma, Malignant | Glioblastoma Multiforme of Brain

United States
Children's Hospital Medical Center, Cincinnati
Novartis

Completed

A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)

Glioblastoma | Malignant Glioma of Brain | High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Brainstem Glioma | Bithalamic High Grade Glioma

United States

Clinical Trials on Advanced Milignant Gliomas in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations